Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2142862 | Lung Cancer | 2010 | 5 Pages |
Abstract
A phase I/II trial of TS-1 combined with gemcitabine was designed to determine the maximum tolerated dose (MTD) and recommended dose (RD) and to evaluate the efficacy and toxicity in elderly patients with advanced non-small cell lung cancer (NSCLC). Patients older than 70 years of age received TS-1 orally b.i.d. on days 1-14 and gemcitabine intravenously on days 8 and 15 every 4 weeks. In phase I (n = 22), each cohort received escalating doses of TS-1 (30-40 mg/m2 b.i.d.) and gemcitabine (800-1000 mg/m2); MTD was 40 mg/m2 b.i.d. TS-1 and 1000 mg/m2 gemcitabine; RD was 30 mg/m2 b.i.d. TS-1 and 1000 mg/m2 gemcitabine. Dose-limiting toxicities included a grade 3 infection, skin toxicity, and stomatitis. In phase II (n = 37), the overall response rate was 27% (90% confidence interval (CI): 15-42%) and the median time to progression and overall survival were 4.2 months (90% CI: 3.2-5.7) and 12.9 months (90% CI: 10.4-14.7), respectively. The most common grade 3 or higher toxicity was neutropenia (45.9%), and thrombocytopenia was observed in 13.5% of patients. Two cases each of grade 3 pneumonitis and skin toxicity were observed, but nonhematological toxicities occurred at generally low frequencies. TS-1 with gemcitabine is a promising doublet regimen in elderly patients with advanced NSCLC with acceptable toxicities.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Takashi Seto, Takeharu Yamanaka, Izumi Wasada, Nobuhiko Seki, Hiroaki Okamoto, Takashi Ogura, Masahiko Shibuya, Yuichi Takiguchi, Tetsu Shinkai, Noriyuki Masuda, Yukito Ichinose, Kenji Eguchi, Koshiro Watanabe,